RxDoctor Payments Data

Josephine Thuo, NP

Psychiatric/Mental Health · Fall River, MANPI 1104443613

Payments from drug & device makers

$2,127in general payments, 2019–2025

Across 91 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$793
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$367
  • Otsuka America Pharmaceutical, Inc.$302
  • Johnson & Johnson$196
  • Alkermes, Inc.$183
  • Corium, LLC$175
  • plus $111 from 3 others

What the payments were for

  • Food & beverage$2,127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,127 in reported general payments places this provider in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$61,343
Medicare patients
125
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl129$193,839
NuplazidPimavanserin Tartrate19$104,402
Invega SustennaPaliperidone Palmitate26$93,917
AustedoDeutetrabenazine12$87,117
Lurasidone Hcl207$54,270
CaplytaLumateperone Tosylate24$39,515
LybalviOlanzapine/Samidorphan Malate18$27,479
Aripiprazole155$13,917
Divalproex Sodium ErDivalproex Sodium159$7,719
Lamotrigine517$6,864
Quetiapine Fumarate342$5,669
Varenicline Tartrate17$5,125
Buspirone Hcl323$5,062
BelsomraSuvorexant11$4,738
Lithium Carbonate ErLithium Carbonate253$4,575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$793$193,839129 claims
Johnson & JohnsonInvega Sustenna$196$93,91726 claims
Teva Pharmaceuticals USA, Inc.Austedo$66$87,11712 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$367$39,51524 claims
Alkermes, Inc.Lybalvi$183$27,47918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →